Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baclofen + tizanidine is a combination of two centrally acting muscle relaxants used for the management of spasticity, particularly in conditions such as multiple sclerosis or spinal cord injury. Baclofen acts primarily as a gamma-aminobutyric acid (GABA) B receptor agonist, inhibiting excitatory neurotransmitter release and reducing muscle spasticity. Tizanidine is an alpha-2 adrenergic receptor agonist that inhibits presynaptic motor neurons, decreasing muscle tone and frequency of spasms. The combination may be used to achieve better control of spasticity at lower doses of each agent, potentially minimizing side effects associated with higher doses of either drug alone. However, additive sedative effects are possible when these drugs are combined[1][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on baclofen + tizanidine.